Sector consensus Arcus Biosciences, Inc.

Stocks

Market Closed - NYSE 16:00:03 2026-08-27 EDT			5-day change	1st Jan Change
30.59 ^USD	-0.55%		+3.62%	+28.37%

08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Average Target P.	Objective/dr gap	Nbr of analysts
ARCUS BIOSCIENCES, INC.	38.33	+24.62%	12
LONZA GROUP AG	681.13	+15.88%	23
REVOLUTION MEDICINES, INC.	230.68	+7.07%	21
IQVIA HOLDINGS INC.	275.17	+5.22%	18
BEONE MEDICINES AG	432.16	+15%	28
CELLTRION, INC.	266,031.64	+37.56%	23
MEDPACE HOLDINGS, INC.	581.83	-6.01%	12
ASCENDIS PHARMA A/S	270.19	+26%	19
EUROFINS SCIENTIFIC SE	72.53	-0.4%	14
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	281	-4.78%	14
ICON PUBLIC LIMITED COMPANY	185.56	+9.85%	16
TEMPUS AI, INC.	63.36	-7.48%	14
BIO-TECHNE CORPORATION	70.73	-2.28%	11
PHARMARON BEIJING CO., LTD.	49.21	+11.39%	10
ABIVAX	138.97	+38.42%	6
PRAXIS PRECISION MEDICINES, INC.	638.68	+69.25%	19
IONIS PHARMACEUTICALS, INC.	88	+38.89%	22
KYMERA THERAPEUTICS, INC.	130.91	+4.27%	22
APOGEE THERAPEUTICS, INC.	134.85	-0.08%	11
GENSCRIPT BIOTECH CORPORATION	3.72	-17.48%	7
Average	13,519.93	+13.24%	16
Weighted average by Cap.	22,739.39	+13.06%	19